Literature DB >> 33459874

Analysis of unplanned hospital readmissions up to 2-years after metastatic spine tumour surgery.

Naresh Kumar1, Andrew Thomas2, Sirisha Madhu2, Miguel Rafael David Ramos2, Liang Shen3, Joel Yong Hao Tan2, Andre Villanueva2, Nivetha Ravikumar2, Gabriel Liu2, Hee Kit Wong2.   

Abstract

PURPOSE: The aim of this study was to investigate rates, causes, and risk factors of unplanned hospital readmissions (UHR) within 30 days, 90 days, 1 year and 2 years after metastatic spine tumour surgery (MSTS) to augment multi-disciplinary treatment planning and improve patient education.
METHODS: We retrospectively reviewed 272-patients who underwent MSTS between 2005 and 2016. Hospital records were utilised to obtain demographics, oncological, procedural details, and postoperative outcomes. All UHR within 2 years were reviewed. Primary outcomes were rates, causes, and risk factors of UHR. Risk factors for UHR were evaluated utilising multivariate logistic regression analysis.
RESULTS: Thirty-day, 90 day, 1 year, and 2 year UHR-rates after MSTS were 17.2%, 31.1%, 46.2%, and 52.7%, respectively. Lung cancer primaries had the highest UHR-events (24.7%) whilst renal/thyroid displayed the least (6.6%). Disease-related causes (16.2%) were the most common reason for readmissions across all timeframes, followed by respiratory (13.7%) and progression of metastatic spine disease (12.7%). Urological conditions accounted for majority of readmissions within 30-days; disease-related causes, symptomatic spinal metastases, and respiratory conditions represented the most common causes at 30-90 days, 90 days-1 year, and 1-2 years, respectively. An ECOG >1 (p = 0.057), CCI >7 (p = 0.01), and primary lung tumour (p = 0.02) significantly increased UHR-risk on multivariate analysis.
CONCLUSION: Seventy-four percent of patients had at least one UHR within 2 years of MSTS and majority were secondary to disease-related causes. Majority of first UHR occurred between 30 and 90 days post-surgery. Local disease progression and overall disease progression account for the highest UHR-events at 90 days-1 year and 1-2 year timeframes, respectively. We define UHR in specific timeframes, thus enabling better surveillance and reducing unnecessary morbidity.

Entities:  

Keywords:  Neoplasm metastasis; Risk factors; Spine; Surgery; Unplanned hospital readmission

Year:  2021        PMID: 33459874     DOI: 10.1007/s00586-021-06723-5

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  18 in total

Review 1.  Diagnosis and management of metastatic spine disease. A review.

Authors:  Daniel M Sciubba; Rory J Petteys; Mark B Dekutoski; Charles G Fisher; Michael G Fehlings; Stephen L Ondra; Laurence D Rhines; Ziya L Gokaslan
Journal:  J Neurosurg Spine       Date:  2010-07

2.  Identification of complications that have a significant effect on length of stay after spine surgery and predictive value of 90-day readmission rate.

Authors:  Sanjay Yadla; George M Ghobrial; Peter G Campbell; Mitchell G Maltenfort; James S Harrop; John K Ratliff; Ashwini D Sharan
Journal:  J Neurosurg Spine       Date:  2015-08-28

3.  Variations in 30-day readmissions and length of stay among spine surgeons: a national study of elective spine surgery among US Medicare beneficiaries.

Authors:  Siddhartha Singh; Rodney Sparapani; Marjorie C Wang
Journal:  J Neurosurg Spine       Date:  2018-06-01

4.  Factors influencing extended hospital stay in patients undergoing metastatic spine tumour surgery and its impact on survival.

Authors:  Naresh Kumar; Ravish Shammi Patel; Samuel Sherng Young Wang; Joel Yong Hao Tan; Aditya Singla; Zhaojin Chen; Nivetha Ravikumar; Amanda Tan; Nandika Kumar; Dennis Hwee Weng Hey; Samuel Vara Prasad; Balamurugan Vellayappan
Journal:  J Clin Neurosci       Date:  2018-07-27       Impact factor: 1.961

5.  Thirty-day readmission and reoperation after surgery for spinal tumors: a National Surgical Quality Improvement Program analysis.

Authors:  Aditya V Karhade; Viren S Vasudeva; Hormuzdiyar H Dasenbrock; Yi Lu; William B Gormley; Michael W Groff; John H Chi; Timothy R Smith
Journal:  Neurosurg Focus       Date:  2016-08       Impact factor: 4.047

6.  Prognostic factors in patients with spinal metastasis: a systematic review and meta-analysis.

Authors:  Panya Luksanapruksa; Jacob M Buchowski; William Hotchkiss; Sasima Tongsai; Sirichai Wilartratsami; Areesak Chotivichit
Journal:  Spine J       Date:  2016-12-14       Impact factor: 4.166

7.  Postoperative quality-of-life assessment in patients with spine metastases treated with long-segment pedicle-screw fixation.

Authors:  Florian Bernard; Jean-Michel Lemée; Olivier Lucas; Philippe Menei
Journal:  J Neurosurg Spine       Date:  2017-03-24

8.  Modeling 1-year survival after surgery on the metastatic spine.

Authors:  Ahmer K Ghori; Dana A Leonard; Andrew J Schoenfeld; Ehsan Saadat; Nathan Scott; Marco L Ferrone; Adam M Pearson; Mitchel B Harris
Journal:  Spine J       Date:  2015-07-06       Impact factor: 4.166

9.  Predictors for surgical complications of en bloc resections in the spine: review of 220 cases treated by the same team.

Authors:  Stefano Boriani; Alessandro Gasbarrini; Stefano Bandiera; Riccardo Ghermandi; Ran Lador
Journal:  Eur Spine J       Date:  2016-03-14       Impact factor: 3.134

10.  Blood Loss and Transfusion Requirements in Metastatic Spinal Tumor Surgery: Evaluation of Influencing Factors.

Authors:  Naresh Kumar; Aye Sandar Zaw; Hnin Ei Khine; Karthikeyan Maharajan; Khin Lay Wai; Barry Tan; Siti Mastura; Raymond Goy
Journal:  Ann Surg Oncol       Date:  2016-01-27       Impact factor: 5.344

View more
  2 in total

1.  Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer.

Authors:  Rong He; Changfeng Man; Jiabin Huang; Lian He; Xiaoyan Wang; Yakun Lang; Yu Fan
Journal:  Front Genet       Date:  2022-04-06       Impact factor: 4.772

Review 2.  Perspectives on Immunotherapy of Metastatic Colorectal Cancer.

Authors:  Yongjiu Dai; Wenhu Zhao; Lei Yue; Xinzheng Dai; Dawei Rong; Fan Wu; Jian Gu; Xiaofeng Qian
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.